The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
SARS-CoV-2 vaccines in development
Open accessAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The potential advantages of inactivated vaccines are non-replicability in the host, non-transmissibility, and the induction of a broad range of humoral and cellular responses against different epitopes.”
In the citing paper
“Their production and scale-up are relatively easy in the context of good yield production systems and the availability of biosafety level 3 facilities.7”
In the citing paper
“8 weeks after the second vaccine injection volunteers showed high levels of IgM, and IgG anti-SARS-CoV-2 spike protein (S) and receptor binding domain (RBD) binding titers3,5,6.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“In agreement with previous reports3,6,9, there was a broad range of plasma neutralizing activity 3–14 weeks after the second vaccine dose that was similar to that elicited by natural infection in a convalescent cohort after 1.3 months, and greater than the activity at 6.2 months after infection (Fig. 1a, Extended Data Table 1).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“In line with previous reports3,6,9, IgG and IgM levels were significantly higher in the vaccinated group compared to a cohort of convalescent patients assayed 1.3 and 6.2 months after infection, while IgA levels were similar (Extended Data Fig 1j–l).”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“However, this and other small studies3,11 cannot accurately predict the half-life of the neutralizing response.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [3]
In the citing paper
“Humans make SARS-CoV-2-specific antibodies, CD4+ T cells, and CD8+ T cells in response to SARS-CoV-2 infection (Grifoni et al., 2020; Krammer, 2020; Stephens and McElrath, 2020) (Figure 1).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Krammer, 2020
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952
Research works printed but not linked: 1
- The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (The National Academies Press, 2020).
Cited by
Sorted by citations
Items 501–600 of 1,004
Kuzmina, A., Wattad, S., Khalaila, Y., Ottolenghi, A., Rosental, B., Engel, S., Rosenberg, E., & Taube, R. (2021) · iScience · doi:10.1016/j.isci.2021.103467 · Cited by 33
Hakim, M. S., & Aman, A. T. (2022) · Viruses · doi:10.3390/v15010048 · Cited by 35
Li, S., Huang, S., Ke, Y., Chen, H., Dang, J., Huang, C., Liu, W., Cui, D., Wang, J., Zhi, X., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100801 · Cited by 31
Raciborski, F., Jankowski, M., Gujski, M., Pinkas, J., & Samel‐Kowalik, P. (2021) · Vaccines · doi:10.3390/vaccines9080832 · Cited by 31
Roßmann, L., Bagola, K., Stephen, T., Gerards, A.-L., Walber, B., Ullrich, A., Schülke, S., Kamp, C., Spreitzer, I., Hasan, M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103651118 · Cited by 31
Rapid Development of Analytical Methods for Evaluating Pandemic Vaccines: A Covid-19 Perspective
Baldwin, J., Piplani, S., Sakala, I. G., Honda‐Okubo, Y., Li, L., & Petrovsky, N. (2021) · Bioanalysis · doi:10.4155/bio-2021-0096 · Cited by 33
Chen, J., Wang, B., Caserto, J. S., Shariati, K., Cao, P., Pan, Y., Xu, Q., & Ma, M. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101714 · Cited by 30
β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)
Córdova, A., Caballero-García, A., Roche, E., & Noriega, D. C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182312636 · Cited by 33
Yasin, A. İ., Aydın, S. G., Sümbül, B., Koral, L., Şimşek, M., Geredeli, Ç., Öztürk, A., Perkin, P., Demirtaş, D., Erdemoğlu, E., et al. (2022) · Future Oncology · doi:10.2217/fon-2021-1248 · Cited by 30
Strategies for fighting pandemic virus infections: Integration of virology and drug delivery
Nakamura, T., Isoda, N., Sakoda, Y., & Harashima, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.046 · Cited by 32
Photonics enabled intelligence system to identify SARS-CoV 2 mutations
Taha, B. A., Al-Jubouri, Q., Mashhadany, Y. I. M. A., Zan, M. S. D., Bakar, A. A. A., Fadhel, M. M., & Arsad, N. (2022) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-022-11930-1 · Cited by 32
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33
Oladipo, E. K., Adeniyi, M. O., Ogunlowo, M. T., Irewolede, B. A., Adekanola, V. O., Oluseyi, G. S., Omilola, J. A., Udoh, A. F., Olufemi, S. E., Adediran, D. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122107 · Cited by 33
Highlights in the fight against COVID-19: does autophagy play a role in SARS-CoV-2 infection?
Delorme‐Axford, E., & Klionsky, D. J. (2020) · Autophagy · doi:10.1080/15548627.2020.1844940 · Cited by 32
A cis-acting ligase ribozyme generates circular RNA in vitro for ectopic protein functioning
Su, C.-I., Chuang, Z.-S., Shie, C.-T., Wang, H.-I., Kao, Y.-T., & Yu, C.-Y. (2024) · Nature Communications · doi:10.1038/s41467-024-51044-y · Cited by 32
Roles, Characteristics, and Analysis of Intrinsically Disordered Proteins: A Minireview
Lermyte, F. (2020) · Life · doi:10.3390/life10120320 · Cited by 32
Current progress and challenges in the design and development of a successful COVID-19 vaccine
Li, T., Zhang, T., Gu, Y., Li, S., & Xia, N. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.011 · Cited by 30
Kalathiya, U., Padariya, M., Fåhræus, R., Chakraborti, S., & Hupp, T. R. (2021) · Biomolecules · doi:10.3390/biom11020297 · Cited by 29
Tsoi, K. K. F., Sung, J. J. �., Lee, H. W. Y., Yiu, K. K. L., Fung, H., & Wong, S. Y. S. (2021) · BMJ Innovations · doi:10.1136/bmjinnov-2021-000661 · Cited by 29
Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 27
A preliminary study of the innate immune memory of Kupffer cells induced by PEGylated nanoemulsions
Liu, M., Su, Y., Chen, M., Wang, J., Liu, M., Dai, Y., Wang, C., Luo, X., Lai, C.-Y., Liu, M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.12.025 · Cited by 30
Meister, T. L., Gottsauner, M., Schmidt, B., Heinen, N., Tödt, D., Audebert, F., Buder, F., Lang, H., Gessner, A., Steinmann, E., et al. (2022) · Virus Research · doi:10.1016/j.virusres.2022.198791 · Cited by 30
Villacampa, A., Alfaro, E., Morales, C., Díaz‐García, E., López-Fernández, C., Bartha, J. L., López-Sánchez, F., Lorenzo, Ó., Moncada, S., Sánchez‐Ferrer, C. F., et al. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01397-6 · Cited by 34
Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
Lederer, K., Parvathaneni, K., Painter, M. M., Bettini, E., Agarwal, D., Lundgreen, K. A., Weirick, M., Goel, R. R., Xu, X., Drapeau, E. M., et al. (2021) · doi:10.1101/2021.09.16.21263686 · Cited by 179
Vacunas frente a SARS-CoV-2 y piel
Galván‐Casas, C., Català, A., & Muñoz‐Santos, C. (2021) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2021.05.011 · Cited by 29
More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing
Jensen, N., Barry, A., & Kelly, A. H. (2022) · Economy and Society · doi:10.1080/03085147.2022.2087899 · Cited by 31
Bouazzaoui, A., & Abdellatif, A. A. H. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100500 · Cited by 31
LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment
Xue, Y., Hou, X., Zhong, Y., Zhang, Y., Du, S., Kang, D. D., Wang, L., Wang, C., Li, H., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57149-2 · Cited by 30
Li, R., Ma, X., Deng, J., Chen, Q., Liu, W., Peng, Z., Qiao, Y., Lin, Y., He, X., & Zhang, H. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00641-8 · Cited by 29
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features
Rowntree, L. C., Chua, B. Y. L., Nicholson, S. R., Koutsakos, M., Hensen, L., Douros, C., Selva, K. J., Mordant, F. L., Wong, C. Y., Habel, J. R., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1258 · Cited by 29
Self-citationTuccori, M., Convertino, I., Ferraro, S., Valdiserra, G., Cappello, E., Fini, E., & Focosi, D. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1960819 · Cited by 27
Lacticaseibacillus paracasei DG enhances the lactoferrin anti-SARS-CoV-2 response in Caco-2 cells
Salaris, C., Scarpa, M., Elli, M., Bertolini, A., Guglielmetti, S., Pregliasco, F. E., Brun, P., & Castagliuolo, I. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1961970 · Cited by 31
Gray, L. T., Raczy, M. M., Briquez, P. S., Marchell, T. M., Alpar, A. T., Wallace, R. P., Volpatti, L. R., Sasso, M. S., Cao, S., Nguyen, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121159 · Cited by 29
Tormo, N., Navalpotro, D., Martínez-Serrano, M., Moreno, M., Grosson, F., Tur, I., Guna, M. R., Soriano, P., Tornero, A., & Gimeno, C. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115573 · Cited by 30
Tcheou, J., Raskin, A. J., Singh, G., Kawabata, H., Bielak, D. A., Sun, W., González‐Domínguez, I., Sather, D. N., García‐Sastre, A., Palese, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791764 · Cited by 28
Self-citationBettinger, J. A., Sadarangani, M., Serres, G. D., Valiquette, L., Vanderkooi, O. G., Kellner, J. D., Muller, M. P., Top, K. A., Isenor, J. E., McGeer, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-051254 · Cited by 29
Gepner, Y., Mofaz, M., Oved, S., Yechezkel, M., Constantini, K., Goldstein, N., Eisenkraft, A., Shmueli, E., & Yamin, D. (2022) · Communications Medicine · doi:10.1038/s43856-022-00090-y · Cited by 29
Recent advances to accelerate purification process development: A review with a focus on vaccines
Keulen, D., Geldhof, G., Bussy, O. L., Pabst, M., & Ottens, M. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.463195 · Cited by 29
Saville, J. W., Berezuk, A., Srivastava, S. S., & Subramaniam, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01062 · Cited by 32
Essa, R. Z., Wu, Y. S., Batumalaie, K., Sekar, M., & Poh, C. L. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00432-6 · Cited by 29
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 32
COVID-19 vaccination and thyroiditis
Şendur, S. N., Oğuz, S. H., & Ünlütürk, U. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101759 · Cited by 30
Advances in nanomedicine for the treatment of infectious diseases caused by viruses
Dash, S. R., & Kundu, C. N. (2023) · Biomaterials Science · doi:10.1039/d2bm02066a · Cited by 29
Liu, M., Zhao, Y. G., Shi, Z., Zink, J. I., & Yu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.3c00644 · Cited by 29
Inclusion of Pregnant and Lactating Persons in COVID-19 Vaccination Efforts
Riley, L. E., & Jamieson, D. J. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0173 · Cited by 32
Younes, S. N., Younes, N., Shurrab, F. M., & Nasrallah, G. K. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2196 · Cited by 26
Murray, M. J., McIntosh, M., Atkinson, C. E., Mahungu, T. W., Wright, E., Chatterton, W., Gandy, M., & Reeves, M. B. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.03.010 · Cited by 28
COVID-19 and Dentistry in 72 Questions: An Overview of the Literature
Derruau, S., Bouchet, J., Nassif, A., Baudet, A., Yasukawa, K., Lorimier, S., Prêcheur, I., Bloch‐Zupan, A., Pellat, B., Chardin, H., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040779 · Cited by 30
A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2
Yoshimoto, F. K. (2021) · The Protein Journal · doi:10.1007/s10930-021-09967-8 · Cited by 28
Cibulski, S. P., Varela, A. P. M., Teixeira, T. F., Cancela, M., Sesterheim, P., Souza, D. O., Roehe, P. M., & Silveira, F. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.632714 · Cited by 29
Jones, D. L., Salazar, A. S., Rodriguez, V. J., Balise, R. R., Starita, C. U., Morgan, K. E., Raccamarich, P. D. C., Montgomerie, E. K., Nogueira, N. F., Ojeda, I. T. B., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab154 · Cited by 28
Shrivastava, T., Singh, B., Rizvi, Z. A., Verma, R., Goswami, S., Vishwakarma, P., Jakhar, K., Sonar, S., Mani, S., Bhattacharyya, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641447 · Cited by 26
COVID-19 Research: Lessons from Non-Human Primate Models
Albrecht, L., Bishop, E., Jay, B., Lafoux, B., Minoves, M., & Passaes, C. (2021) · Vaccines · doi:10.3390/vaccines9080886 · Cited by 30
Sampson, A., Heeney, J. L., Cantoni, D. M., Ferrari, M., Sans, M. S., George, C. L., Genova, C. D., Neto, M. M., Einhauser, S., Asbach, B., et al. (2021) · Viruses · doi:10.3390/v13081579 · Cited by 27
Halfmann, P., Castro, A., Loeffler, K., Frey, S. J., Chiba, S., Kawaoka, Y., & Kane, R. S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10253 · Cited by 27
Neutralizing Antibodies and Antibody-Dependent Enhancement in COVID-19: A Perspective
Ajmeriya, S., Kumar, A., Karmakar, S., Rana, S., & Singh, H. (2022) · Journal of the Indian Institute of Science · doi:10.1007/s41745-021-00268-8 · Cited by 29
Kim, S. J., Yao, Z., Marsh, M., Eckert, D. M., Kay, M. S., Lyakisheva, A., Pasic, M. D., Bansal, A., Birnboim, C., Jha, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31300-9 · Cited by 28
Metabolomics Markers of COVID-19 Are Dependent on Collection Wave
Lewis, H.-M., Liu, Y., Frampas, C., Longman, K., Spick, M. P., Stewart, A., Sinclair, E. L., Kasar, N., Greener, D., Whetton, A. D., et al. (2022) · Metabolites · doi:10.3390/metabo12080713 · Cited by 28
The SARS-CoV-2 Spike Protein Activates the Epidermal Growth Factor Receptor-Mediated Signaling
Palakkott, A. R., Alneyadi, A. H., Muhammad, K., Eid, A. H., Amiri, K. M. A., Ayoub, M. A., & Iratni, R. (2023) · Vaccines · doi:10.3390/vaccines11040768 · Cited by 28
COVID-19 vaccination in pregnant and lactating women
Kaziród, K., Kuryło, W., Brzuszkiewicz, K., Miturski, A., & Semczuk‐Sikora, A. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.09.023 · Cited by 27
Park, J., Park, M., Kim, J., Heo, Y., Han, B. H., Choi, N., Park, C., Lee, R., Lee, D., Chung, S. H., et al. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115316 · Cited by 27
Nagib, M., Sayed, A. M. M., Korany, A. H., Abdelkader, K., Shari, F. H., Mackay, W. G., & Rateb, M. E. (2024) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-024-10436-8 · Cited by 26
Chau, C. Y. C., Chow, L. L. W., Sridhar, S., & Shih, K. C. (2021) · Ophthalmology and Therapy · doi:10.1007/s40123-021-00338-1 · Cited by 27
Liu, Z., Wu, H., Egland, K. A., Gilliland, T. C., Dunn, M. D., Luke, T. C., Sullivan, E. J., Klimstra, W. B., Bausch, C. L., & Whelan, S. P. J. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1940652 · Cited by 26
Wu, S., Xia, Y., Hu, Y., & Ma, G. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113871 · Cited by 27
Gil-Manso, S., Carbonell, D., López-Fernández, L. A., Miguens, I., Alonso, R., Buño, I., Muñóz, P., Ochando, J., Pion, M., & Correa‐Rocha, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.726960 · Cited by 26
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
Al-Jighefee, H. T., Najjar, H., Ahmed, M. N., Qush, A., Awwad, S., & Kamareddine, L. (2021) · Vaccines · doi:10.3390/vaccines9101196 · Cited by 29
Aileni, M., Rohela, G. K., Jogam, P., Soujanya, S., & Zhang, B. (2022) · Cells · doi:10.3390/cells11071182 · Cited by 30
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 30
Drug repurposing for the treatment of COVID-19
Kato, Y., Nishiyama, K., Nishimura, A., Noda, T., Okabe, K., Kusakabe, T., Kanda, Y., & Nishida, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.04.007 · Cited by 35
Davenport, B., Catala, A., Weston, S. M., Johnson, R. M., Ardanuy, J., Hammond, H., Dillen, C. A., Frieman, M. B., Catalano, C. E., & Morrison, T. E. (2022) · npj Vaccines · doi:10.1038/s41541-022-00481-1 · Cited by 28
Metal-based strategies for the fight against COVID-19
Li, H., Yuan, S., Wei, X., & Sun, H. (2022) · Chemical Communications · doi:10.1039/d2cc01772e · Cited by 27
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc?
Baronti, A., Gentile, F., Manetti, A. C., Scatena, A., Pellegrini, S., Pucci, A., Franzini, M., Castiglione, V., Maiese, A., Giannoni, A., et al. (2022) · Viruses · doi:10.3390/v14081644 · Cited by 27
Implications of Neural Plasticity in Retinal Prosthesis
Caravaca-Rodriguez, D., Gaytan, S. P., Suaning, G. J., & Barriga‐Rivera, A. (2022) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.63.11.11 · Cited by 30
Olmedillas, E., Mann, C. J., Peng, W., Wang, Y.-T., Díaz-Avalos, R., Bedinger, D., Valentine, K. M., Shafee, N., Schendel, S. L., Yuan, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.441046 · Cited by 23
A review of currently licensed mucosal COVID-19 vaccines
Tscherne, A., & Krammer, F. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127356 · Cited by 26
Self-citationTrimeric SARS-CoV-2 Spike Proteins Produced from CHO Cells in Bioreactors Are High-Quality Antigens
Pino, P., Kint, J., Kiseljak, D., Agnolon, V., Corradin, G., Kajava, A. V., Rovero, P., Dijkman, R., den Hartog, G., McLellan, J. S., et al. (2020) · Processes · doi:10.3390/pr8121539 · Cited by 28
Otero‐Romero, S., Sánchez‐Montalvá, A., & Vidal‐Jordana, Á. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1886924 · Cited by 28
Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
Abdel-Moneim, A. S., Abdelwhab, E. M., & Memish, Z. A. (2021) · Virology · doi:10.1016/j.virol.2021.02.007 · Cited by 27
Angiotensin-converting enzyme 2, coronavirus disease 2019, and abdominal aortic aneurysms
Xu, B., Li, G., Guo, J., Ikezoe, T., Kasirajan, K., Zhao, S., & Dalman, R. L. (2021) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2021.01.051 · Cited by 26
SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity
Blasi, F., Gramegna, A., Sotgiu, G., Saderi, L., Voza, A., Aliberti, S., & Amati, F. (2021) · Respiratory Medicine · doi:10.1016/j.rmed.2021.106355 · Cited by 27
Zhang, Y. V., Wiencek, J. R., Meng, Q. H., Theel, E. S., Babić, N., Sepiashvili, L., Pecora, N., Slev, P. R., Cameron, A., & Konforte, D. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab051 · Cited by 27
SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor
Offersgaard, A., Hernandez, C. R. D., Pihl, A. F., Costa, R., Venkatesan, N., Lin, X., Pham, L. V., Feng, S., Fahnøe, U., Scheel, T. K. H., et al. (2021) · Vaccines · doi:10.3390/vaccines9070706 · Cited by 26
Chatterjee, R., Ghosh, M., Sahoo, S., Padhi, S., Misra, N., Raina, V., Suar, M., & Son, Y. (2021) · Vaccines · doi:10.3390/vaccines9080812 · Cited by 27
Frantz, P. N., Barinov, A., Ruffié, C., Combredet, C., Najburg, V., de Melo, G. D., Larrous, F., Kergoat, L., Teeravechyan, S., Jongkaewwattana, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26506-2 · Cited by 26
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges
Terrier, O., Si‐Tahar, M., Ducatez, M., Chevalier, C., Pizzorno, A., Goffic, R. L., Crépin, T., Simon, G., & Naffakh, N. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010106 · Cited by 28
T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants
Nguyen, T. H. O., Cohen, C. A., Rowntree, L. C., Bull, M. B., Hachim, A., Kedzierska, K., & Valkenburg, S. A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.793102 · Cited by 24
Santana-Mederos, D., Pérez-Nicado, R., Climent-Ruíz, Y., Rodríguez, L., Ramírez, B. S., Perez-Rodriguez, S., Rodriguez, M., Labrada, C., Hernández, T., Díaz-Hernández, M., et al. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00200g · Cited by 26
Lafon, E., Jäger, M., Bauer, A., Reindl, M., Bellmann‐Weiler, R., Wilflingseder, D., Lass‐Flörl, C., & Posch, W. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.013 · Cited by 27
Juncker, H. G., Mulleners, S. J., Ruhé, E. J. M., Coenen, E. R. M., Bakker, S., van Doesburg, M., Harinck, J. E., Rood, R. D., Bouhuijs, J. H., Oomen, M., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101393 · Cited by 25
A new approach for determining SARS-CoV-2 epitopes using machine learning-based in silico methods
Cihan, P., & Özger, Z. B. (2022) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2022.107688 · Cited by 27
Buisson, Y. (2022) · La Presse Médicale · doi:10.1016/j.lpm.2022.104131 · Cited by 29
Zamfir, M.-A., Moraru, L., Dobrea, C. M., Scheau, A.-E., Iacob, S. A., Moldovan, C., Scheau, C., Căruntu, C., & Căruntu, A. (2022) · Medicina · doi:10.3390/medicina58070874 · Cited by 28
Azad, T., Singaravelu, R., Taha, Z., Jamieson, T. R., Boulton, S., Crupi, M. J. F., Martin, N. T., Fekete, E. E. F., Poutou, J., Ghahremani, M., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.007 · Cited by 24
Li, H., Cheng, C., Li, S., Wu, Y., Liu, Z., Liu, M., Chen, J., Zhong, Q., Zhang, X., Liu, S., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113242 · Cited by 25
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Sharma, G., Saha, R. P., & Lee, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e5 · Cited by 26
Development of COVID-19 vaccines utilizing gene therapy technology
Nakagami, H. (2021) · International Immunology · doi:10.1093/intimm/dxab013 · Cited by 25
Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants
Jukič, M., Škrlj, B., Tomšič, G., Pleško, S., Podlipnik, Č., & Bren, U. (2021) · Molecules · doi:10.3390/molecules26103003 · Cited by 28
Zhang, Z., Liu, Q., Sun, Y., Li, J., Liu, J., Pan, R., Cao, L., Chen, X., Li, Y., Zhang, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1964385 · Cited by 25
Pal, M., Musib, D., Zade, A. J., Chowdhury, N., & Roy, M. (2021) · ChemistrySelect · doi:10.1002/slct.202101852 · Cited by 25
Metadata
- Authors
- Krammer, F.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Krammer, Florian
- ORCID
- Krammer, Florian
- Venue
- Nature
- Published
- 2020-09-23
- Volume
- 586
- Issue
- 7830
- Pages
- 516-527
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3087924281
- Cited by
- 2,098
- References
- 101
- Citations by year
- 2026: 91 · 2025: 147 · 2024: 173 · 2023: 287 · 2022: 538 · 2021: 747 · 2020: 112
- FWCI
- 19.97
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (cc-by)
- Funders
- JPB Foundation (2020-215611, HHSN272201400008C, 75N93019C00051)
- Open Philanthropy Project (#2020-215611, 75N93019C00051, HHSN272201400008C)
- National Institute of Allergy and Infectious Diseases (HHSN272201400008C), 75N93019C00051, 2020-215611, HHSN272201800048C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, COVID-19 vaccines, vaccine development, vaccine candidate, clinical trials, animal studies, vaccine safety, vaccine efficacy, COVID-19 pandemic
- MeSH terms
- Drug Development, COVID-19, COVID-19 Vaccines, Animals, Clinical Trials as Topic, Drug Industry, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Immunity, Mucosal, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
